Association of CK19 expression with the efficacy of adjuvant transarterial chemoembolization after hepatic resection in hepatocellular carcinoma patients at high risk of recurrence
Background and Aim: This study retrospectively explored the potential association between CK19 expression and efficacy of adjuvant conventional transarterial chemoembolization (TACE) after hepatic resection in patients with hepatocellular carcinoma (HCC) at high risk of recurrence.
Methods: Patients (n = 508) who underwent hepatic resection between January 2012 and December 2017 were enrolled. Overall survival (OS) and recurrence-free survival (RFS) were compared between groups. Survival analysis was performed using the Kaplan-Meier method, and groups were compared using the log-rank test.
Results: OS and RFS were worse for CK19-positive patients than for CK19-negative patients, regardless of whether patients were matched on the basis of propensity scores. Among CK19-positive patients in the absence of propensity score matching, TACE was associated with better RFS. Among CK19-negative patients in the absence of propensity matching, TACE was associated with better OS and RFS. Among patients treated with TACE, CK19-positive patients showed worse OS but similar RFS as CK19-negative patients. Multivariate analysis identified the following independent predictors of worse OS: CK19 positivity, no adjuvant TACE, macrovascular invasion, microvascular invasion, tumor size >5 cm, alanine transaminase >80 U/L, and aspartate transaminase >80 U/L. Multivariate analysis identified the following predictors of worse RFS: CK19 positivity, no adjuvant TACE, age ≥60 years, alpha-fetoprotein ≥400 ng/ml, and Barcelona Clinic Liver Cancer stage B/C.
Conclusion: This study suggests that among HCC patients at high risk of recurrence, adjuvant TACE can significantly prolong OS and RFS of CK19-negative patients, while it may prolong only RFS of CK19-positive patients.
Relevance for Patients: Not all patients will benefit from adjuvant TACE, therefore, it is necessary to select the best benefit subsets before TACE. By studying the relationship between CK19 expression and TACE benefit, it will be possible to help guide decision-making about adjuvant TACE in HCC patients at high risk of recurrence.
[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics
2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49.
[2] Zhong JH, Xing BC, Zhang WG, Chan AW, Chong CC, Serenari M, et al. Repeat Hepatic Resection Versus
Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma: A Retrospective Multicentre Study. Br J Surg
2022;109(1):71-8.
[3] An C, Kim DW, Park YN, Chung YE, Rhee H, Kim MJ. Single Hepatocellular Carcinoma: Preoperative MR
Imaging to Predict Early Recurrence after Curative Resection. Radiology 2015;276:433-43.
[4] Yuan BH, Zhu YK, Zou XM, Zhou HD, Li RH, Zhong JH. Repeat Hepatic Resection Versus Ablation for Patients
with Recurrent Hepatocellular Carcinoma: A Systematic Review. BJS Open 2022:Online ahead of print.
[5] Chan AW, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, et al. Development of Pre and Post-operative Models to Predict Early Recurrence of Hepatocellular Carcinoma after Surgical Resection. J Hepatol 2018;69:1284-93.
[6] Xing H, Sun LY, Yan WT, Quan B, Liang L, Li C, et al. Repeat Hepatectomy for Patients with Early and Late Recurrence of Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Analysis. Surgery 2021;169:911-20.
[7] Korean Liver Cancer A, National Cancer Center GK. 2018 Korean Liver Cancer Association-National Cancer
Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 2019;20:1042-113.
[8] Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific Clinical Practice Guidelines on
the Management of Hepatocellular Carcinoma: A 2017 Update. Hepatol Int 2017;11:317-70.
[9] Konno T. Targeting Cancer Chemotherapeutic Agents by Use of Lipiodol Contrast Medium. Cancer 1990;66:1897-903.
[10] Wang Z, Ren Z, Chen Y, Hu J, Yang G, Yu L, et al. Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. Clin Cancer Res 2018;24:2074-81.
[11] Wei W, Jian PE, Li SH, Guo ZX, Zhang YF, Ling YH, et al. Adjuvant Transcatheter Arterial hemoembolization
after Curative Resection for Hepatocellular Carcinoma Patients with Solitary Tumor and Microvascular Invasion:
ARandomized Clinical Trial of Efficacy and Safety. Cancer Commun (Lond) 2018;38:61.
[12] Qi YP, Zhong JH, Liang ZY, Zhang J, Chen B, Chen CZ, et al. Adjuvant Transarterial Chemoembolization for
Patients with Hepatocellular Carcinoma Involving Microvascular Invasion. Am J Surg 2019;217:739-44.
[13] Esagian SM, Kakos CD, Giorgakis E, Burdine L, Barreto JC, Mavros MN. Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers (Basel) 2021;13:2984.
[14] Zhong JH, Li H, Li LQ, You XM, Zhang Y, Zhao YN, et al. Adjuvant Therapy Options Following Curative Treatment of Hepatocellular Carcinoma: A Systematic Review of Randomized Trials. Eur J Surg Oncol 2012;38:286-95.
[15] Zhong JH, Li LQ. Postoperative Adjuvant Transarterial Chemoembolization for Participants with Hepatocellular Carcinoma: AMeta-analysis. Hepatol Res 2010;40:943-53.
[16] Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, et al. Guidelines for the Diagnosis and Treatment of
Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720.
[17] Sakamoto I, Aso N, Nagaoki K, Matsuoka Y, Uetani M, Ashizawa K, et al. Complications Associated with
Transcatheter Arterial Embolization for Hepatic Tumors. Radiographics 1998;18:605-19.
[18] Lai JP, Conley A, Knudsen BS, Guindi M. Hypoxia after Transarterial Chemoembolization May Trigger a
Progenitor Cell Phenotype in Hepatocellular Carcinoma. Histopathology 2015;67:442-50.
[19] Xiang X, Lau WY, Wu ZY, Zhao C, Ma YL, Xiang BD, et al. Transarterial Chemoembolization Versus Best Supportive Care for Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombusa Multicenter Study. Eur J Surg Oncol 2019;45:1460-7.
[20] Greenhill C. Hepatocellular Carcinoma: How does Keratin 19 Influence HCC? Nat Rev Gastroenterol Hepatol 2013;10:565.
[21] Takano M, Shimada K, Fujii T, Morita K, Takeda M, Nakajima Y, et al. Keratin 19 as a Key Molecule in
Progression of Human Hepatocellular Carcinomas through Invasion and Angiogenesis. BMC Cancer 2016;16:903.
[22] Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, et al. The Clinicopathological and Prognostic
Relevance of Cytokeratin 7 and 19 Expression in Hepatocellular Carcinoma. A Possible Progenitor Cell Origin. Histopathology 2006;49:138-51.
[23] Bader BL, Magin TM, Hatzfeld M, Franke WW. Amino Acid Sequence and Gene Organization of Cytokeratin No. 19, an Exceptional Tail-less Intermediate Filament Protein. EMBO J 1986;5:1865-75.
[24] Zhong JH, Ke Y, Zhu SL, Wang L, Luo CP, Gong WF, et al. Adefovir Dipivoxil is Less Expensive than Lamivudine and Associated with Similar Prognosis in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Radical Resection. Onco Targets Ther 2016;9:6897-907.
[25] Ke Y, Ma L, You XM, Huang SX, Liang YR, Xiang BD, et al. Antiviral Therapy for Hepatitis B Virus-related
Hepatocellular Carcinoma after Radical Hepatectomy. Cancer Biol Med 2013;10:158-64.
[26] Zhong JH, Ke Y, Gong WF, Xiang B, Ma L, Ye XP, et al. Hepatic Resection Associated with Good Survival for
Selected Patients with Intermediate and Advanced-stage Hepatocellular Carcinoma. Ann Surg 2014;260:329-40.
[27] Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is it Adherent to
the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group. Ann Surg
2013;257:929-37.
[28] Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, et al. Partial Hepatectomy vs. Transcatheter Arterial Chemoembolization for Resectable Multiple Hepatocellular Carcinoma beyond Milan Criteria: A RCT. J Hepatol 2014;61:82-8.
[29] Zhong JH, Li LQ. Portal Hypertension Should not be a Contraindication of Hepatic Resection to Treat Hepatocellular Carcinoma with Compensated Cirrhosis. Hepatology 2015;62:977-8.
[30] Zhong JH, Lu SD, Wang YY, Ma L, Li LQ. Intermediatestage HCC--upfront Resection can be Feasible. Nat Rev Clin Oncol 2015;12:c4.
[31] Peng Z, Chen S, Xiao H, Wang Y, Li J, Mei J, et al. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma. Radiology 2019;292:237-47.
[32] Sun DW, Zhang YY, Sun XD, Chen YG, Qiu W, Ji M, et al. Prognostic Value of Cytokeratin 19 in Hepatocellular Carcinoma: A Meta-analysis. Clin Chim Acta 2015;448:161-9.
[33] Mehrpouya M, Pourhashem Z, Yardehnavi N, Oladnabi M. Evaluation of Cytokeratin 19 as a Prognostic Tumoral and Metastatic Marker with Focus on Improved Detection Methods. J Cell Physiol 2019;234:21425-35.
[34] Zhuo JY, Lu D, Tan WY, Zheng SS, Shen YQ, Xu X. CK19- positive Hepatocellular Carcinoma is a Characteristic
Subtype. J Cancer 2020;11:5069-77.
[35] Nouri YM, Kim JH, Yoon HK, Ko HK, Shin JH, Gwon DI. Update on Transarterial Chemoembolization with DrugEluting Microspheres for Hepatocellular Carcinoma. Korean J Radiol 2019;20:34-49.
[36] Xie ZB, Wang XB, Peng YC, Zhu SL, Ma L, Xiang BD, et al. Systematic Review Comparing the Safety and Efficacy of Conventional and Drug-eluting Bead Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma. Hepatol Res 2015;45:190-200.
[37] Lu J, Zhao M, Arai Y, Zhong BY, Zhu HD, Qi XL, et al. Clinical Practice of Transarterial Chemoembolization for Hepatocellular Carcinoma: Consensus Statement from an International Expert Panel of International Society
of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surg Nutr 2021;10:661-71.
[38] Deng ZJ, Li L, Teng YX, Zhang YQ, Zhang YX, Liu HT, et al. Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy. J Clin Transl Hepatol 2021. Online ahead of print.
[39] Chen K, Wei W, Liu L, Deng ZJ, Li L, Liang XM, et al. Lenvatinib with or without Immune Checkpoint Inhibitors for Patients with Unresectable Hepatocellular Carcinoma in Real-world Clinical Practice. Cancer Immunol Immunother 2021. Online ahead of print.